Skip to main content

Table 2 Baseline characteristics overall and by induction immunosuppression CTP

From: Pilot study comparing the childhood arthritis and rheumatology research alliance consensus treatment plans for induction therapy of juvenile proliferative lupus nephritis

  All
n = 41
CYC
n = 24
MMF
n = 17
p-value
Demographics
 Age at enrollment in years, mean (SD) 14.7 (2.8) 15.2 (2.9) 14 (2.6) 0.146
 Age at SLE diagnosis in years, mean (SD) 13.8 (2.8) 13.8 (2.9) 13.7 (2.7) 0.832
 SLE duration in weeks, median (IQR) 6 (1–73) 14 (3, 120) 5 (1, 10) 0.130
 Female, n (%) 34 (83) 18 (75) 16 (94) 0.109
 Race, n (%)     0.889
  White 16 (39) 10 (42) 6 (35)  
  Black or African American 11 (27) 6 (25) 5 (29)  
  Asian or Pacific Islander 6 (15) 4 (17) 2 (12)  
  Other 8 (19) 4 (17) 4 (24)  
 Hispanic ethnicity, n (%) 11 (27) 6 (25) 5 (29) 0.753
 Parental Income in US $/year, n/total (%) 0.798
   < 25,000 6/26 (23) 4/15 (27) 2/11 (18)
  25–49,999 8/26 (31) 3/15 (20) 5/11 (45)
  50–74,999 2/26 (8) 1/15 (7) 1/11 (9)
  75–99,999 6/26 (23) 4/15 (27) 2/11 (18)
  100–150,000 2/26 (8) 2/15 (13) 0/11
   > 150,000 2/26 (8) 1/15 (7) 1/11 (9)
 Insured, n (%) 36 (88) 20 (83) 16 (94) 0.382
Clinical and laboratory characteristics
 Lupus nephritis class, n (%)     0.005
  ISN-RPS Class III, n (%) 16 (39) 5 (21) 11 (65)  
  ISN-RPS Class IV, n (%) 25 (61) 19 (79) 6 (35)  
 Concurrent ISN-RPS Class V LN, n (%) 14 (34) 6 (25) 8 (47) 0.142
 GFR in ml/min/1.73 m2, median (IQR)a 94 (70–107) 93 (79–107) 95 (67–123) 0.864
 Proteinuria in mg pr/mg cr, median (IQR)b 1.9 (1.1–4.7) 1.9 (1.3–4.6) 1.8 (0.8–4.7) 0.554
 Hematuria present, n/total (%) 29/40 (73) 22/23 (96) 7/15 (47) 0.001
 Hypertension, n/total (%)c 23/37 (62) 13/20 (65) 10/17 (59) 0.699
 ESR in mm/hr., mean (SD) 50 (33) 44 (27) 60 (41) 0.304
 Complement factor 3, median (IQR) 51 (39–75) 51 (39–71) 55 (31–98) 0.685
 Complement factor 4, median (IQR) 6 (4–8) 6 (3–8) 6 (4–14) 0.578
 Elevated dsDNA, n/total (%) 32/36 (89) 20/22 (91) 12/14 (86) 0.629
 Antiphospholipid antibody present, n/total (%) 24/40 (60) 14/24 (58) 10/16 (63) 0.792
 SLEDAI-2 K, median (IQR) 12 (8–20) 16 (10–20) 12 (6–22) 0.458
 PGA, scale 0–10, median (IQR) 5 (3–6) 5 (3–6) 6 (2–6) 0.707
 SLICC Damage Index, n/total (%)     0.677
  Total Score 0 30/37 (81) 17/22 (77) 13/15 (87)  
  Total Score 1 7/37 (19) 5/22 (23) 2/15 (13)  
  1. Abbreviations: CTP consensus treatment plan, dsDNA double stranded DNA antibody, CR creatinine, GFR glomerular filtration rate, IQR interquartile range, ISN-RPS International Society of Nephrology-Renal Pathology Society, IQR interquartile range, PGA Physician’s global disease activity, PR protein, SD standard deviation, SLEDAI-2 K systemic lupus erythematosus disease activity index-2000, SLICC systemic lupus international collaborating clinics
  2. aGFR estimated using modified Schwartz equation
  3. bProteinuria assessed by spot urine protein to creatinine ratio
  4. cHypertension defined as systolic or diastolic blood pressure ≥ 90th percentile, [21]